COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma

This post hoc analysis of the COMPARZ study (pazopanib, n = 557; sunitinib, n = 553) supported similar efficacy of first-line pazopanib and first-line sunitinib treatment in advanced renal cell carcinoma. Patients who required dose modifications because of toxicity received higher cumulative doses w...

Descripción completa

Detalles Bibliográficos
Autores principales: Sternberg, Cora N., Motzer, Robert J., Hutson, Thomas E., Choueiri, Toni K., Kollmannsberger, Christian, Bjarnason, Georg A., Nathan, Paul, Porta, Camillo, Grünwald, Viktor, Dezzani, Luca, Han, Jackie, Tannir, Nizar M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518515/
https://www.ncbi.nlm.nih.gov/pubmed/31601514
http://dx.doi.org/10.1016/j.clgc.2019.01.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518515/
https://www.ncbi.nlm.nih.gov/pubmed/31601514
http://dx.doi.org/10.1016/j.clgc.2019.01.015

Ejemplares similares